The RSI Oscillator for CERS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 25 of the 28 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 80 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +1.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 167 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 56 cases where CERS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CERS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.734) is normal, around the industry mean (4.204). P/E Ratio (-78.000) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
XAIR saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned positive. In 84 of the 101 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XAIR's RSI Oscillator exited the oversold zone, 34 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +7.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where XAIR advanced for three days, in 177 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
XAIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 45 cases where XAIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XAIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for XAIR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.144) is normal, around the industry mean (4.170). P/E Ratio (-0.038) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.213) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. XAIR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XAIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CERS | XAIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 100 | |
PRICE GROWTH RATING 1..100 | 47 | 91 | |
P/E GROWTH RATING 1..100 | 19 | 8 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (9) in the Medical Specialties industry is in the same range as XAIR (41) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as XAIR (100) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.
CERS's SMR Rating (94) in the Medical Specialties industry is in the same range as XAIR (100) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.
CERS's Price Growth Rating (47) in the Medical Specialties industry is somewhat better than the same rating for XAIR (91) in the null industry. This means that CERS’s stock grew somewhat faster than XAIR’s over the last 12 months.
XAIR's P/E Growth Rating (8) in the null industry is in the same range as CERS (19) in the Medical Specialties industry. This means that XAIR’s stock grew similarly to CERS’s over the last 12 months.
| CERS | XAIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 72% | N/A |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 75% | 6 days ago 77% |
| Declines ODDS (%) | 27 days ago 83% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 2 FA rating(s) are green while XAIR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 4 TA indicator(s) are bullish while XAIR’s TA Score has 4 bullish TA indicator(s).
CERS (@Medical/Nursing Services) experienced а -2.50% price change this week, while XAIR (@Medical/Nursing Services) price change was +3.27% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.01%. For the same industry, the average monthly price growth was -7.51%, and the average quarterly price growth was -8.84%.
CERS is expected to report earnings on Feb 25, 2027.
XAIR is expected to report earnings on Nov 11, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CERS | 1D Price Change % | ||
|---|---|---|---|---|
| CERS | 100% | -0.85% | ||
| ICUI - CERS | 46% Loosely correlated | -0.34% | ||
| UTMD - CERS | 45% Loosely correlated | -0.75% | ||
| RVTY - CERS | 44% Loosely correlated | +7.84% | ||
| ATRC - CERS | 43% Loosely correlated | +0.89% | ||
| DHR - CERS | 43% Loosely correlated | +0.94% | ||
More | ||||
A.I.dvisor indicates that over the last year, XAIR has been loosely correlated with OPK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if XAIR jumps, then OPK could also see price increases.
| Ticker / NAME | Correlation To XAIR | 1D Price Change % | ||
|---|---|---|---|---|
| XAIR | 100% | +4.98% | ||
| OPK - XAIR | 35% Loosely correlated | N/A | ||
| KIDS - XAIR | 32% Poorly correlated | +3.22% | ||
| CERS - XAIR | 31% Poorly correlated | -0.85% | ||
| IDXX - XAIR | 31% Poorly correlated | +0.06% | ||
| RVTY - XAIR | 31% Poorly correlated | +7.84% | ||
More | ||||